推迟新冠疫苗的第二剂接种。 - Suppr

Suppr

超能文献

Delaying the second dose of covid-19 vaccines.

作者信息

Pimenta Dominic, Yates Christian, Pagel Christina, Gurdasani Deepti

机构信息

Healthcare Workers' Foundation, London, UK.

Department of Mathematical Sciences, University of Bath, Bath, UK.

出版信息

BMJ. 2021 Mar 18;372:n710. doi: 10.1136/bmj.n710.

DOI:10.1136/bmj.n710

PMID:33737404

Abstract

摘要

相似文献

Delaying the second dose of covid-19 vaccines.推迟新冠疫苗的第二剂接种。

BMJ. 2021 Mar 18;372:n710. doi: 10.1136/bmj.n710.

Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2.采用ChAdOx1 nCoV-19和BNT162b2进行异源初免-加强免疫接种。

Lancet Infect Dis. 2021 Sep;21(9):1212-1213. doi: 10.1016/S1473-3099(21)00420-5. Epub 2021 Jul 29.

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.异源初免-加强型新型冠状病毒肺炎疫苗接种：初始反应原性数据

Lancet. 2021 May 29;397(10289):2043-2046. doi: 10.1016/S0140-6736(21)01115-6. Epub 2021 May 12.

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.英格兰长期护理机构居民中 ChAdOx1 nCoV-19 与 BNT162b2 疫苗首针接种对 SARS-CoV-2 感染的疫苗有效性（VIVALDI）：一项前瞻性队列研究。

Lancet Infect Dis. 2021 Nov;21(11):1529-1538. doi: 10.1016/S1473-3099(21)00289-9. Epub 2021 Jun 23.

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.在英国（Com-COV2）进行的包含 mRNA、病毒载体和蛋白佐剂疫苗的异源 COVID-19 初级疫苗接种的免疫原性、安全性和反应原性：一项单盲、随机、2 期、非劣效性试验。

Lancet. 2022 Jan 1;399(10319):36-49. doi: 10.1016/S0140-6736(21)02718-5. Epub 2021 Dec 6.

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.在英国，用 ChAdOx1 nCov-19 或 BNT162b2 接种两剂后作为第三剂（加强针）接种 7 种 COVID-19 疫苗的安全性和免疫原性（COV-BOOST）：一项盲法、多中心、随机、对照、2 期试验。

Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2.

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.一剂接种和加强针接种时间对 ChAdOx1 nCoV-19（阿斯利康）疫苗免疫原性和有效性的影响：四项随机试验的 pooled 分析。

Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19.

Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.针对 SARS-CoV-2 的三种不同疫苗加强免疫后的抗体反应动力学。

Front Immunol. 2022 Jan 19;13:811020. doi: 10.3389/fimmu.2022.811020. eCollection 2022.

Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.辉瑞-BioNTech 和牛津-阿斯利康 COVID-19 疫苗对预防 80 岁及以上人群住院的有效性：一项基于病例对照研究的无效性试验。

Lancet Infect Dis. 2021 Nov;21(11):1539-1548. doi: 10.1016/S1473-3099(21)00330-3. Epub 2021 Jun 23.

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.新冠病毒疫苗接种后和 SARS-CoV-2 阳性检测后的血小板减少症和血栓栓塞风险：自身对照病例系列研究。

BMJ. 2021 Aug 26;374:n1931. doi: 10.1136/bmj.n1931.

引用本文的文献

Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study.ChAdOx1 nCoV-19（Vaxzevria）初级系列疫苗对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）贝塔和德尔塔变异株的有效性：一项全国性研究。

BMC Infect Dis. 2025 Aug 17;25(1):1028. doi: 10.1186/s12879-025-11410-7.

[Lessons from the Russian Flu for the endgame of the current pandemic-an exit strategy for Germany].[俄罗斯流感对当前大流行终局的启示——德国的退出策略]

Pravent Gesundh. 2022;17(3):257-265. doi: 10.1007/s11553-021-00882-5. Epub 2021 Aug 5.

COVID-19 vaccines: current and future challenges.新冠疫苗：当前及未来的挑战

Front Pharmacol. 2024 Nov 6;15:1434181. doi: 10.3389/fphar.2024.1434181. eCollection 2024.

COVID-19 vaccine updates for people under different conditions.不同人群的 COVID-19 疫苗更新信息。

Sci China Life Sci. 2024 Nov;67(11):2323-2343. doi: 10.1007/s11427-024-2643-1. Epub 2024 Jul 29.

COVID-19 vaccination challenges: A mini-review.COVID-19 疫苗接种挑战：小型综述。

Hum Vaccin Immunother. 2022 Nov 30;18(5):2066425. doi: 10.1080/21645515.2022.2066425. Epub 2022 May 5.

Study of immunogenicity, safety and efficacy of covishield vaccine among health care workers in a tertiary cardiac care centre.在一家三级心脏护理中心的卫生保健工作者中研究 covishield 疫苗的免疫原性、安全性和有效性。

Indian J Med Microbiol. 2022 Apr-Jun;40(2):200-203. doi: 10.1016/j.ijmmb.2022.03.003. Epub 2022 Apr 11.

Optimizing COVID-19 vaccination programs during vaccine shortages.在疫苗短缺期间优化新冠疫苗接种计划。

Infect Dis Model. 2022 Mar;7(1):286-298. doi: 10.1016/j.idm.2022.02.002. Epub 2022 Feb 25.

Should We Delay the Second COVID-19 Vaccine Dose in Order to Optimize Rollout? A Mathematical Perspective.为优化推广，我们是否应延迟第二剂 COVID-19 疫苗接种？数学视角。

Int J Public Health. 2022 Jan 24;66:1604312. doi: 10.3389/ijph.2021.1604312. eCollection 2021.

Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis.新型冠状病毒2疫苗在真实世界研究中的有效性和安全性：一项系统评价与荟萃分析

Infect Dis Poverty. 2021 Nov 14;10(1):132. doi: 10.1186/s40249-021-00915-3.

Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA.接种BNT162b2 mRNA疫苗后五种商用抗SARS-CoV-2总抗体和IgG免疫测定法的比较。

J Med Biochem. 2021 Sep 3;40(4):335-340. doi: 10.5937/jomb0-31475.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验